论文部分内容阅读
目的观察高三尖杉脂碱（HHT）治疗慢性粒细胞白血病（CML）的临床疗效。方法自1994年12月～1997年12月应用HHT及羟基脲（Hu）联合治疗CML21例作为治疗组，a-干扰素治疗CML19例作为对照组，分别观察、比较有效率。结果治疗组临床和血液学完全缓解16例（76.2％）;部分缓解3例（143％），总有效率90.5％;细胞遗传学转阴率14.3％，分子生物学转阴率14.3％。其中有1例从加速期转变为慢性期。对照组有效率、细胞遗传学转阴率和分子生物学转阴率与治疗组相仿。而且HHT治疗CML毒副作用小。结论HHT是经济、实惠、有效的治疗CML方法。
Objective To observe the clinical efficacy of high-harringtonine (HHT) in the treatment of chronic myelogenous leukemia (CML). Methods From December 1994 to December 1997, 21 patients with CML were treated with HHT and hydroxyurea (Hu) as the treatment group, and 19 patients with CML treated with a-interferon were used as the control group. The observation and comparison were effective. Results In the treatment group, 16 cases (76.2%) achieved complete clinical and hematological remission, 3 cases (143%) partially relieved, and the total effective rate was 90.5%. The cytogenetic negative rate was 14.3%, and the molecular biology negative rate was 14.3%. One of these cases changed from the accelerated phase to the chronic phase. The control group’s efficiency, cytogenetic negative rate, and molecular biology negative rate were similar to those of the treatment group. And HHT treatment of CML has little side effects. Conclusion HHT is an economical, effective and effective treatment for CML.